Pneumologie 1999; 53(9): 426-432
DOI: 10.1055/s-1999-9034
ÜBERSICHT
Georg Thieme Verlag Stuttgart ·New York

Rationale Kombination für die Asthmatherapie

Salmeterol und Fluticason in einem PräparatR. Wettengel1 , G. Steinkamp2
  • 1Karl-Hansen-Klinik, Bad Lippspringe
  • 2Lübeck
Further Information

Publication History

Publication Date:
31 December 1999 (online)

Also available at
 

Zusammenfassung

Die aktuellen Empfehlungen der Deutschen Atemwegsliga sehen zur Basistherapie des mittelgradigen und schweren Asthma bronchiale eine Kombination aus inhalativem Kortikoid und langwirkendem β2-Sympathomimetikum, alternativ auch mit Theophyllin vor. Ein neues Kombinationspräparat aus Salmeterol und Fluticason im Pulverapplikationssystem Diskus® ist in drei Wirkstärken verfügbar, die sich in ihrem Kortikoidanteil unterscheiden (entweder 100, 250 oder 500 μg Fluticason pro Dosis), während die Salmeterol-Dosis mit jeweils 50 μg identisch ist. Mit der zweimal täglichen Inhalation einer Dosis wird gleichzeitig Entzündungshemmung und langwirkende Bronchodilatation erreicht. Gegenüber der alleinigen Behandlung mit einem der Einzelstoffe (Salmeterol oder Fluticason) erwies sich die Wirksamkeit des Kombinationspräparates als überlegen. Eine Einsparung inhalativer Kortikoide war möglich. Bei Patienten mit stabilem Asthma kann die Verordnung dieses Präparates zu einer Vereinfachung der Therapie führen und dazu beitragen, daß die verordnete Langzeittherapie zuverlässiger durchgeführt wird.

Literatur

  • 1 Baker J, Yancey S, Kalberg C, Petrocella V, Emmett A, Bowers B, Rickard K. Added salmeterol versus increased-dose fluticasone in patients symptomatic on low-dose fluticasone.  Am J Respir Crit Care Med. 1998;  157 406
    PubMedGoogle Scholar
  • 2 Barnes P J, Godfrey S, Magnussen H. Asthma bronchiale. London; Martin Dunitz Ltd. 1997
  • 3 Bateman E D, Britton M, Carrillo J, Almeida J, Wixon C. Salmeterol/fluticason combination inhaler.  Clin Drug Invest. 1998;  16 193-201
    CrossrefPubMedGoogle Scholar
  • 4 Buhl R, Kardos P, Magnussen H, Matthys H, Sauer R, Schauer P, Vogelmeier C, Wettengel R, Worth H, Menz G. Feste Kombination inhalierbarer Kortikoide und langwirkender β2-Sympathomimetika zur Langzeittherapie des Asthma bronchiale.  Pneumologie. 1999;  53 210-212
    PubMedGoogle Scholar
  • 5 Campbell D A, McLennan G, Coates J R, Frith P A, Gluyas P A, Latimer K M, Luke C G, Martin A J, Roder D M, Ruffin R E. A comparison of asthma deaths and near-fatal asthma attacks in South Australia.  Eur Respir J. 1994;  7 490-497
    CrossrefPubMedGoogle Scholar
  • 6 Cook D, Srebro S H, Rogenes P R, Rickard K, Edwards L, Johnson M C. A comparison of the safety and efficacy of fluticasone, triamcinolone, and fluticasone plus salmeterol in patients with mild to moderate asthma.  Am J Respir Crit Care Med. 1998;  157 A416
    PubMedGoogle Scholar
  • 7 D'Alonzo G E, Tolep K A. Salmeterol in the treatment of chronic asthma.  Am Fam Physician. 1997;  56 558-562
    PubMedGoogle Scholar
  • 8 Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms.  Eur Respir Rev. 1997;  7:49 338-343
    PubMedGoogle Scholar
  • 9 Edwards T, Gross G, Mitchell D, Chervinsky P, Woodring A, Baitinger L, Prillaman B, House K, Shah T. The salmeterol xinafoate/fluticasone propionate dry powder combination product via diskus inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate dry powder alone.  Am J Respir Crit Care Med. 1998;  157 A414
    PubMedGoogle Scholar
  • 10 Gerrits C MJM, Herings R MC, Lammers J WJ, Leufkens H GM. Too low usage of inhaled steroids among patients with long-acting β2-agonists.  Eur Respir J. 1998;  12 156-P1106
    PubMedGoogle Scholar
  • 11 Glaxo Wellcome .Study SFCA 3003: Salmeterol/fluticasone combination product (50/250) improves asthma control (Data on file). 1998
  • 12 Greening A P, Ind P W, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid.  Lancet. 1994;  344 219-224
    CrossrefPubMedGoogle Scholar
  • 13 Gross G, Woodring A, Prillaman B, House K, Shah T. Efficacy and safety of the salmeterol/fluticasone propionate (50/100 μg) dry powder combination inhaler in patients with asthma.  Eur Respir J. 1998;  12 156-P1104
    PubMedGoogle Scholar
  • 14 Ind P W, Negro R, Fletcher C P, Browning D C, James M H. Inhaled salmeterol and fluticasone propionate therapy in moderate adult asthma.  Eur Respir J. 1997;  10 1-P0149
    CrossrefPubMedGoogle Scholar
  • 15 Janson C, Chinn S, Jarvis D, Burney P. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey.  Eur Respir J. 1997;  10 1795-1802
    CrossrefPubMedGoogle Scholar
  • 16 Johansson H, McIvor R A, Purello F, D'Ambrosio C, Gratziou C, James M H. Salmeterol/fluticasone propionate combination dry powder inhaler (50/100 μg BID) is more effective than budesonide (400 μg BID) in mild to moderate asthma.  Eur Respir J. 1998;  12 P162
    PubMedGoogle Scholar
  • 17 Johansson L O. A comparison of once-daily of fluticasone propionate (FP) 200 μg and budesonide (BUD) 400 μg twice-daily.  Am J Respir Crit Care Med. 1998;  157 A404
    PubMedGoogle Scholar
  • 18 Mann M C, Eliasson O, Patel K, ZuWallack R L. An evaluatin of severity-modulated compliance with q.i.d. dosing of inhaled beclomethasone.  Chest. 1992;  102 1342-1346
    PubMedGoogle Scholar
  • 19 Muir J F, Bertin L, Georges D. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial.  French Multicentre Study Group. Eur Respir J. 1992;  5 1197-1200
    PubMedGoogle Scholar
  • 20 National Heart, L. a. B. I., WHO . Global strategy for asthma management and prevention.  NHLBI/WHO Workshop Report. 1995;  Publ. No. 95-3659
    PubMedGoogle Scholar
  • 21 Nowak D, Volmer T, Wettengel R. Asthma bronchiale - eine Krankheitskostenanalyse.  Pneumologie. 1996;  50 364-371
    PubMedGoogle Scholar
  • 22 Nutini S, Martini T, Righi R. Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline.  Respir Med. 1998;  92 683-690
    PubMedGoogle Scholar
  • 23 Paggiaro P L, Giannini D, Franco A, Testi R. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction European Study Group.  Eur Respir J. 1996;  9 1689-1695
    CrossrefPubMedGoogle Scholar
  • 24 Pauwels R A, Lofdahl C G, Postma D S, Tattersfield A E, O'Byrne P, Barnes P J, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.  N Engl J Med. 1997;  337 1405-1411
    CrossrefPubMedGoogle Scholar
  • 25 Pieters W R, Ringdal N, Aubier M, Chapman K, Huskisson S C. A new inhaler combination containing salmeterol and fluticasone propionate is well-tolerated in longterm use.  Eur Respir J. 1998;  12 20-P164
    PubMedGoogle Scholar
  • 26 Pieters W R, Steinmetz K O, Aubier M, Johnson L, Gomez E, Bogolubov M. Effectiveness of a new salmeterol/fluticasone propionate (50/500 μg) combination inhaler in patients with reversible airways obstruction.  Eur Respir J. 1998;  12 35-P0329
    CrossrefPubMedGoogle Scholar
  • 27 Pollard S J, Spector S L, Yancey S W, Cox F M, Emmett A. Salmeterol versus theophylline in the treatment of asthma.  Ann Allergy Asthma Immunol. 1997;  78 457-464
    PubMedGoogle Scholar
  • 28 Reese P R, Mahajan P, Woodring A. Salmeterol/fluticasone propionate combination product improves quality of life in asthma patients.  Eur Respir J. 1998;  12 35-P0325
    CrossrefPubMedGoogle Scholar
  • 29 Ringdal N, Chapman K R, Backer V, Palmqvist M, Saarelainen S, Briggs M. Asthma control with salmeterol and fluticasone propionate (50/250 μg) given twice daily in a single combination DiskusTM (AccuhalerTM) inhaler compared to salmeterol 50 μg and fluticasone propionate 250 μg given twice daily via two separate Diskus inhalers.  Eur Respir J. 1998;  12 36-P0330
    PubMedGoogle Scholar
  • 30 Schlosser N JJ, Steinmetz K O, Aubier M, Gomez E, Wixon C. Evaluation of longterm safety of salmeterol/fluticasone propionate (50/500 μg) combination inhaler in patients with reversible airways obstruction.  Eur Respir J. 1998;  12 3-P0343
    CrossrefPubMedGoogle Scholar
  • 31 Schultze-Werninghaus G. Neue Erkenntnisse zu allergisch bedingten Atemwegserkrankungen.  Deutsches Ärzteblatt. 1997;  94 523-528
    PubMedGoogle Scholar
  • 32 Selroos O. The pharmacologic and clinical properties of Oxis (formoterol) Turbuhaler.  Allergy. 1998;  53 14-19
    PubMedGoogle Scholar
  • 33 Ukena D, Koper I, Braun H, Leutz M, Schlimmer P, Sybrecht G W. Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline-comparison of effectiveness and tolerance.  Pneumologie. 1997;  51 317-323
    PubMedGoogle Scholar
  • 34 Berg N J, Ossip M, Hederos C A, Anttila H, Davies P. Combination salmeterol xinafoate and fluticasone propionate (50/100 μg strength) bd via one DiskusTM (Accuhaler TM) inhaler compared with salmeterol xinafoate 50 μg and fluticasone propionate 100 μg bd via two separate diskus inhalers.  Eur Respir J. 1998;  12 157-P1108
    PubMedGoogle Scholar
  • 35 Noord J A, Schreurs A JM, Mulders P GH, Mol S JM. Comparison of the efficacy of doubling the dose fluticasone propionate (FP) and adding salmeterol (SLM) in patients with mild-to-moderate asthma.  Am J Respir Crit Care Med. 1997;  155 100s
    PubMedGoogle Scholar
  • 36 Mutius E, Weiland S K, Fritzsch C, Duhme H, Keil U. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany.  Lancet. 1998;  351 862-866
    CrossrefPubMedGoogle Scholar
  • 37 Wettengel R, Berdel D, Hofmann D, Krause J, Kroegel C, Kroidl R F, Leupold W, Lindemann H, Magnussen H, Meister R. et al . Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen.  Pneumologie. 1998;  52 591-601
    PubMedGoogle Scholar
  • 38 Woolcock A, Lundback B, Ringdal N, Jacques L A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.  Am J Respir Crit Care Med. 1996;  153 1481-1488
    PubMedGoogle Scholar

Prof. Dr. med. Ralf Wettengel

Karl-Hansen-Klinik GmbH

Antoniusstr. 19

D-33175 Bad Lippspringe